Liver Meeting 2026 to Convene in Denver

The American Association for the Study of Liver Diseases will host its annual meeting in Denver, Colorado for the first time, November 5 to 9.

Updated on Nov. 5, 2026 in Weight Loss

The Liver Meeting 2026, the annual meeting of the American Association for the Study of Liver Diseases, will run November 5 to 9 at the Colorado Convention Center in Denver. It marks the first time the meeting is held in Denver and carries the theme ELEVATE.

Why it matters

The meeting brings together clinicians and researchers as two therapies are now approved for metabolic dysfunction-associated steatohepatitis (MASH), a condition affecting the liver. Denver-area clinicians and patients stand to see the latest research on treatment as the disease's prevalence grows.

The meeting offers more than 265 hours of programming and over 2500 posters, while an electronic health record analysis compared 2873 adults starting semaglutide 2.4 mg with 2285 starting resmetirom. Outcomes of the head-to-head comparison and long-term effects remain open questions for the sessions to address.

The players

American Association for the Study of Liver Diseases (AASLD)

AASLD is a professional medical society focused on liver disease research, education and clinical practice, and it organizes The Liver Meeting each year.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a biopharmaceutical company that markets resmetirom, one of the approved therapies for MASH.

The details

Topics include an academic debate weighing resmetirom against semaglutide as first-line treatment for MASH with stage 2 to 3 fibrosis, and Madrigal Pharmaceuticals will add 13 real-world abstracts on resmetirom adherence and treatment patterns, the largest spanning more than 12,000 patients. AASLD will also debut the Liver Care for Frontline Clinicians program.

November 5 to 9, 2026: The Liver Meeting 2026 at the Colorado Convention Center in Denver
2050: Projected year that about 41.4% of US adults, or 122 million people, are expected to have metabolic dysfunction-associated steatotic liver disease

Health Landscape

The Liver Meeting, AASLD's annual conference, continues to serve as the field's main venue for presenting liver disease research, and this year's program reflects the arrival of two approved MASH therapies. The shift from mostly trial-based evidence toward real-world patient data signals how treatment of fatty liver disease is being evaluated.

Patients with fatty liver disease in the Denver area may hear about newly approved treatment options and how they compare with other medications as clinicians discuss the research. Conversations with a liver specialist can help determine whether any of these approaches fit an individual's situation.

The takeaway

Fatty liver disease is becoming more common, so understanding the latest treatment research can help people have informed conversations with their doctors. Asking a clinician how new therapies compare with lifestyle approaches is a practical first step.